不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
新型药物时代弥漫大 B 细胞淋巴瘤患者的治疗序贯
英文原题：Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
查看英文原题
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是最常见的侵袭性淋巴瘤，约占成人淋巴瘤病例的40%。约三分之二的DLBCL患者可通过一线治疗治愈，但仍有三分之一患者属于原发难治，或在初始应答后复发，即复发/难治性DLBCL（r/r DLBCL）。近年来，DLBCL治疗通过多种新药取得进展，包括单克隆抗体、抗体药物偶联物（ADC）、双特异性T细胞衔接器（BiTE）以及靶向CD19的嵌合抗原受体（CAR）T细胞疗法。治疗选择不断增加，显著改善了患者结局，但治疗决策流程也日益复杂。本综述概述DLBCL患者的新型疗法，并探讨从一线、二线、三线到后续治疗线次的潜在治疗排序。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma, accounting for ~40% of all cases in adults. Whilst approximately two-thirds of DLBCL patients can be cured by first-line therapy, one-third of patients are primary refractory or relapse after an initial response (r/r DLBCL). Recent advances in the treatment of DLBCL have been achieved by a plethora of novel drugs, such as monoclonal antibodies, antibody-drug conjugates (ADC), bi-specific T-cell engagers (BITEs), and CD-19 directed chimeric antigen receptor (CAR)-T-cell therapies.
The increasing number of therapeutic options significantly improved the outcome of patients; however, the therapeutic algorithm has become increasingly complex. In this review, we provide an overview of novel therapies for DLBCL patients and potential treatment sequencing from first to second, third, and later lines.
论文信息
- 作者
- Karsten IE、Shumilov E、Schmitz N、Lenz G
- 单位
- Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, Muenster, Germany.Germany
- 文献类型
- 综述
- 期刊
- British journal of haematology2024 Dec
- 原文标识
- PubMed 39466716 · DOI 10.1111/bjh.19860
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →